{
  "url": "https://openlegislation.uk/human-medicines-regulations-2012/regulation-183",
  "json_url": "https://openlegislation.uk/human-medicines-regulations-2012/regulation-183.json",
  "legislation": "uksi/2012/1916",
  "legislation_title": "The Human Medicines Regulations 2012",
  "legislation_url": "https://openlegislation.uk/human-medicines-regulations-2012",
  "path": "regulation/183",
  "kind": "regulation",
  "number": "183",
  "heading": "Exception to obligation to operate risk management system",
  "text": "(1) The holder is not required to operate a risk management system under regulation 182(2)(c) in relation to a medicinal product which has an authorisation or registration that was granted before 21st July 2012.\n(2) The licensing authority may impose an obligation on the holder to operate a risk management system in relation to a medicinal product referred to in paragraph (1) if there are concerns about new or changed risks affecting the risk-benefit balance of that product.\n(3) Paragraphs (4) to (6) apply where the licensing authority imposes an obligation to operate a risk management system on the holder under paragraph (2).\n(4) The licensing authority must without delay notify the holder in writing of—\n(a) the imposition of the obligation;\n(b) the justification for the obligation;\n(c) the timeframe for submission of the detailed description of the risk management system required under paragraph (8)(a); and\n(d) the opportunity to present written observations in accordance with paragraph (5).\n(5) Where the holder so requests before the end of the period of thirty days beginning on the day after the receipt by the holder of the notice referred to in paragraph (4), the licensing authority must provide the holder with an opportunity to present written observations in response to the imposition of the obligation within such a time limit as the licensing authority may specify.\n(6) Where a holder presents written observations under paragraph (5), the licensing authority must withdraw or confirm the imposition of the obligation under paragraph (2), having regard to the written observations, as soon as is reasonably practicable.\n(7) Paragraphs (8) and (9) apply where the licensing authority—\n(a) imposes an obligation under paragraph (2) and the holder does not present written obligations under paragraph (5); or\n(b) confirms the imposition of the obligation under paragraph (2) pursuant to paragraph (6).\n(8) The holder must—\n(a) submit to the licensing authority in writing a detailed description of the risk management system which it intends to introduce for the product in accordance with the timeframe set out in the notification under paragraph (4); and\n(b) comply with the obligation to operate a risk management system.\n(9) Where the imposition relates to a product with a UK marketing authorisation, the licensing authority must vary the authorisation to include the measures to be taken as part of the risk management system as conditions of the authorisation as if they were conditions imposed under regulation 59 (conditions of UK marketing authorisations: general).",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2012/1916/regulation/183",
    "retrieved_at": "2026-10-29T01:24:34.993203+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}